Anthera Pharmaceuticals Receives “Buy” Rating from Zacks (ANTH)
Anthera Pharmaceuticals logoAnthera Pharmaceuticals (NASDAQ:ANTH)‘s stock had its “buy” rating reissued by Zacks in a report issued on Friday. They currently have a $5.75 price target on the stock. Zacks‘s price objective would indicate a potential upside of 26.37% from the stock’s previous close.
Zacks’ analyst wrote, “Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat serious illnesses, including cardiovascular and autoimmune diseases. The Company’s clinical-stage programs include one Phase 3 ready program, A-002, and two Phase 2 clinical programs, A-623 and A-001. A-002 and A-001 inhibit a novel enzyme target known as secretory phospholipase A2, or sPLA2. Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease. A-623 targets elevated levels of B-lymphocyte stimulator, or BLyS (also known as BAFF), which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple sclerosis, Sjogren’s Syndrome, Graves’ Disease and others. Anthera Pharmaceuticals, Inc. is headquartered in Hayward, California. “
A number of other analysts have also recently weighed in on ANTH. Analysts at Piper Jaffray raised their price target on shares of Anthera Pharmaceuticals to $7.50 in a research note on Monday, March 30th. Separately, analysts at Jefferies Group reiterated a “buy” rating and set a $12.00 price target (down previously from $18.00) on shares of Anthera Pharmaceuticals in a research note on Tuesday, March 17th.
Anthera Pharmaceuticals (NASDAQ:ANTH) traded up 6.06% during mid-day trading on Friday, hitting $4.55. The stock had a trading volume of 275,372 shares. Anthera Pharmaceuticals has a 52 week low of $1.46 and a 52 week high of $6.37. The stock’s 50-day moving average is $4. and its 200-day moving average is $3.. The company’s market cap is $132.36 million.
Anthera Pharmaceuticals (NASDAQ:ANTH) last released its earnings data on Monday, March 16th. The company reported ($0.32) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.33) by $0.01. Analysts expect that Anthera Pharmaceuticals will post $-1.17 EPS for the current fiscal year.
